Let's start with a free medical database. There are many databases, large and small, but the real users are large, reaching a certain frequency of use. Here are three most comprehensive recommendations:
①: Drug Bank Database is a reliable bioinformatics and chemoinformatics database established by researchers in university of alberta. DrugBank contains 500,000 kinds of drug information, including 2,653 kinds of approved small molecule drugs, 1, 4 1 kinds of approved biotechnology (protein/peptide) drugs, 1 kinds of nutritional products and 645 1 kinds of experimental drugs.
②: Pharnexloud is a highly open Chinese interface medical database, which contains a lot of integrated information such as global drug research and development pipeline, review and approval progress, global clinical trials, China clinical trials, drug bidding, centralized procurement, consistency evaluation and so on.
③ Clinical trial, a network-based resource, provides patients, their families, health care professionals, researchers and the public with convenient access to public and private supported clinical research information on various diseases and obstacles. This website is maintained by the National Library of Medicine (NIH) of the National Institutes of Health. The resources provided by NIH explored 422,494 studies in all 50 states and 2,265,438+0 countries. Note: All materials and related research are for reference only and have not been evaluated by relevant government agencies.
Free database is relatively single in data level and limited in data depth. After all, this kind of database does not spend enough manpower cost and time cost to clean, organize and maintain data like commercial databases.
Commercial medical database is often the representative of high-value database. The characteristic of commercial medicine database is powerful, which can not only integrate academic information, but also analyze the whole life cycle data of drugs, sales details of competing drugs, bidding, investment and financing, centralized procurement information of competing enterprises and so on. In addition, it can track the latest information of product pipeline in real time, adjust the strategic direction in real time, and prevent wasting enterprise resources by doing useless work. Now the commercial database can be said to be an essential database for pharmaceutical enterprises. The author lists the commercial medical databases mainly used by domestic pharmaceutical companies (and compares two foreign databases).
Pharnexcloud, Pharmaceutical Rong Yun Enterprise Edition
Data comprehensiveness: ★★★★★★★
Operating enterprise: Rong Yun Digital Technology.
Online time: 2020
Number of databases: 2 18
Product composition: Ten sections, including drug research and development database, listed drug database, drug sales database, market information database, consistency evaluation database, API database, medical device database, production inspection database, rational drug use database and medical literature.
Data sources: national drug regulatory agencies, experimental research, academic conference reports, literature and periodicals, heterogeneous resources, enterprise announcements, national health institutions, medical news magazines, network information, patents, associations and societies, etc.
Data characteristics: Data were collected from nearly 80 mainstream countries, and 65438+ 10,000 medical data information sources were monitored globally. The data amplification model algorithm involves various characteristic parameters, such as demography, economics, incidence and distribution of medical resources.
Value-added service: ① Special person meets the demand and team solves the problem. (2) Salons, lecture tours, summits, project transactions, demand docking and other activities can all be added to their ecological chain of drug integration circle.
Advantages: It covers all aspects of the entire industrial chain in the medical field, and has done a good job in data volume, data sources, professional reports, data algorithms, and results display.
Disadvantages: Compared with the world's top cortellis, informa, etc. Pharnexcloud's data show that the correlation of the results still has obvious room for improvement.
Pharnexcloud medical database came from behind and made rapid progress. In recent years, it has gradually become the medical database chosen by domestic pharmaceutical companies. Because the product has comprehensive functions and comprehensive data, it is more and more recognized, and I hope to maintain this pace of progress.
Medical wisdom
Comprehensive recommendation index: ★★★★★☆.
Operating enterprise: Chongqing Kangzhou Data
Online time: 2009
Product composition: It consists of nine sections: R&D, consistency, production, listing, market, medication, medical treatment, Chinese herbal medicines and equipment.
Data sources: regional organizations, information, enterprise announcements, medical conferences, company annual reports, medical and health institutions, medical journals, patents, trademarks, technical implementation documents, academic conferences, technical reports, scientific and technological journals, etc.
Number of databases: 172
Search mode, function points, underlying data architecture and interface display: basically consistent with insight and Pharnexcloud databases.
Advantages: The comprehensive report, evaluation and clinical data of drugs are quite good. This is the only company that has launched a cosmetics and food database.
Disadvantages: the drug sales data are not mature enough at the beginning, and there are few global data. Drug sales data is the most important thing in drug project research, competitive product sales analysis and sales strategic goal formulation. There is a need to increase the number of innovative drugs.
Medical cube
Comprehensive recommendation index: ★★★★★☆.
Operating enterprise: Beijing Huabin Licheng
Online time: 20 13
Number of databases: 49
Product composition: capital perspective, global new drugs, global clinic, basic data and market insight.
Data sources: laboratory research, internal meetings, professional reports, patents, trademarks, technical implementation documents, academic conferences, technical reports, scientific journals, documents, teaching materials, regional institutions, information, news information, company annual reports, etc.
Product Highlights: The capital perspective and innovative drug sector are both very good, and they are both industry leaders in this field.
Charge: domestic unit price is high.
Advantages: investment and financing plate, visual disease map is fully related to target integration, evaluation and clinical data. The newly launched NextMed plate has a certain lead, and its investment and financing plate has done a good job.
Disadvantages: the overall data is small, and drug research and development only interprets more than 30,000 drugs. Compared with similar products, some functional blocks are lost and the global data is not rich enough. Although there is a sales data module, it is very closed, without any publicity, and the industry does not know its specific situation.
Medical Rubik's Cube, as one of the databases of innovative drugs and medical investment and financing, has many domestic users at present, but its product functions are too closed and it has become a wall of its own.
Du Yao
Comprehensive recommendation index: ★★★☆.
Operating enterprise: Du Yaojingwei Information Technology
Online time: 20 13
Number of databases: 132
Product composition: It consists of eight sections: global drugs, global devices, investment ecology, clinical research, patent documents, policies and regulations, world drug questions and data customization.
Data sources: laboratory research, internal meetings, professional reports, patents, trademarks, technical implementation documents, academic conferences, technical reports, scientific journals, online databases, online dictionaries, e-book libraries, regional institutions, information, corporate announcements, medical conferences, etc.
Advantages: Its drug R&D information has a good correlation with domestic evaluation and clinical databases, and its hierarchical structure, labels and interfaces are quite good. Fine labels such as biological drugs and chemical drugs are optimized separately.
Disadvantages: There is no drug sales data at present, the data collection of clinical and listed drugs is weak, and the overall data volume is weak in the industry.
As one of the oldest medical databases in China, Du Yao focuses on developing consulting business with global R&D data as its core. The lack of sales data and its core data leads to its data business can only support its consulting business at a low price.
Minet
Comprehensive recommendation index: ★★★★★☆.
Operating enterprise: Guangzhou punctuation medical information
Online time: 20 10 years
Number of databases: 72
Product composition: drug sales (multi-layer structure, hospital, retail), review progress, listed drugs, clinical trials, bid-winning data, global new drug research and development, global patents, and project progress.
Product features: Hospital sales data of leading domestic pharmaceutical sales enterprises are based on "three terminals and six markets", and stratified sampling of multi-level hospitals is extended to the whole country. Urban public hospitals, county-level public hospitals, physical pharmacies, online pharmacies, urban community health centers, township hospitals and other dimensions are complete.
Advantages: South Hospital background, hospital sales data algorithm and R&D data are very good. The six major patterns are second to none in China. Recently, exclusive e-commerce data was launched. Although the industry is still debating the credibility of e-commerce data, it has already taken this step first.
Disadvantages: the comprehensiveness is relatively weak, and the global data, research and development data and approval data except sales data are relatively low, and the version has not made great progress.
The South Institute of Minei medical database has the widest coverage of hospital sales, but other parts are relatively weak.
Dingxiangyuan insight
Comprehensive recommendation index: ★★★☆.
Operating enterprise: Guanlan Network in Hangzhou
Online time: 20 13 insight (headquarters in 2006)
Product composition: clinical trial, progress report, drug library, listed products, pharmaceutical enterprises, bidding, consistency evaluation, medical news, biological products, global data and other ten sections.
Data sources: internal meetings, professional reports, patents, trademarks, online databases, online dictionaries, e-book libraries, heterogeneous resource sharing platforms, knowledge bases, regional institutions, information, corporate announcements, medical conferences, news information, etc.
Product features: Its interface functions are rich, especially the application of small icons is good in domestic UI design, which is different from similar products.
Search mode, function points, underlying data architecture and interface display: basically consistent with the database of drug intelligence.
Advantages: domestic data such as search experience, UI small functions, time axis, registration data, domestic drug review and listing approval are all very good.
Disadvantages: there are few market and sales-related data, and the global R&D data is in its infancy (global drug R&D data is very important to pharmaceutical companies, which can be described as the weather vane of the pharmaceutical industry, and its importance in the global drug pattern, drug project research and enterprise development strategy direction is self-evident).
As a typical representative of the old medical database, Insight is backed by the big tree of Lilac Garden Group. At present, it is one of the databases with many users in China. However, due to the late start of drug research and development data, drug market and sales data, the overall advantages are affected.
PDB Shanghai medical engineering college
Comprehensive recommendation index: ★★★★
Operating enterprise: Shanghai Digital Health Medicine Technology
Online time: 20 1 1 year
Number of databases: 3 1
Product composition: divided into two databases: drug synthesis and new drug research and development monitoring; The drug comprehensive database includes five sections: domestic market, market segments, global market, domestic industrial production and enterprise economic operation. New drug R&D monitoring database includes five sections: global R&D, China R&D, consistency evaluation, enterprise competition and variety screening analysis.
Data sources: patents, trademarks, technical implementation documents, academic conferences, technical reports, sci-tech periodicals, documents, teaching materials, regional institutions, information, news information, company annual reports, pjb, etc.
Advantages: the background of the Ministry of Industry and Information Technology is well-known, and it is the originator of domestic medical databases. The review and clinical data have a good correlation display; The newly launched RPDB retail sector has obvious advantages; RAS medical prescription analysis system has certain exclusivity.
Disadvantages: data comprehensiveness is relatively low, data update in some industries is slow, and UI design is too traditional. As one of the oldest medical databases in China, PDB's data collection of global drug research and development is in the primary stage. Perhaps it is the design problem of the underlying architecture, and only a CPM (new drug research and development monitoring database) has been opened, which leads to some poor correlation.
Ke Rui Vian Kotlis
Comprehensive recommendation index: ★★★★★☆.
Product composition: Cortellis database includes Cortellis competitive intelligence, Cortellis early drug discovery, CMC, generic drugs, API, system biology Metacore and other modules. , mainly composed of competitive information, disease profiles, regulatory information, news and drug discovery information.
Data sources: major drug regulatory agencies, news magazines, online information, literature and periodicals, academic reports, patents and trademarks, company annual reports, etc.
Search method, function point and underlying data architecture: these three dimensions are basically the same as informa database, but the style of presentation is different.
Advantages: It shows the relevance of results, professional reports and data dimensions very well.
Disadvantages:? Lack of systematic drug sales data, there are many lags and a few errors in pipeline monitoring of enterprises in China, and lack of data analysis of US Food and Drug Administration in China.
Cortellis medical database is one of the well-known medical databases in the international medical field at present. Because it is not acclimatized, the proportion of users in China is not so large.
Human information
Comprehensive recommendation index: ★★★☆.
Product composition: Biomedtracker, Pharmaprojects, Sitetrove, Trialtrave, Datamonitor Healthcare, In Vivo, Medtech Insight, Pink Sheet and Scrip.
Data sources: national drug regulatory agencies, medical and health institutions, news magazines, online information, literature journals, academic reports, patents and trademarks, company annual reports, search engines, academic conferences, etc.
Search method, function point and underlying data architecture: these three dimensions are basically the same as cortellis database, but the style of presentation is different, which is more in line with Chinese usage habits.
Advantages: it can comprehensively calculate the drug approval rate, update the data history, and do a good job in news data traceability, display result correlation and data dimension.
Disadvantages: there is no sales data, no generic information, lack of data interpretation by the US Food and Drug Administration in China, and the pipeline tracking of China enterprises is lagging behind;
Informa medical database is one of the mainstream medical databases in the world at present. The "global drug R&D part" of pharne cloud's Pharmaprojects part has been compared by customers, and its share is low due to the price and lack of domestic approval data. At present, the main domestic customers are mainly universities.
A * * * wrote the evaluation of 9 mainstream databases currently used in China and 2 foreign medical databases. Each database has its own characteristics, you can choose according to your own situation.